Acetyl-UBA52/RPS27A/UBB/UBC (K27) Antibody

What is UBA52 and what is its function in cellular processes?

UBA52 (Ubiquitin A-52 residue ribosomal protein fusion product 1) is a hybrid gene that encodes a fusion protein consisting of ubiquitin at the N-terminus and ribosomal protein L40 at the C-terminus. This fusion protein is cleaved post-translationally to produce free ubiquitin and RPL40 . UBA52 plays a crucial role in the ubiquitin-proteasome system (UPS), which is responsible for protein degradation in eukaryotic cells.

The ubiquitin component derived from UBA52 is involved in tagging proteins for degradation through a process called ubiquitination. Research has demonstrated that UBA52-derived ubiquitin is essential for various cellular processes including protein quality control, DNA repair, cell cycle regulation, and stress responses . The ribosomal protein L40 component, on the other hand, is incorporated into the 60S ribosomal subunit and participates in protein synthesis.

Recent studies have highlighted the importance of UBA52 in neurodegenerative disorders, particularly Parkinson's disease, where it has been shown to be crucial in HSP90 ubiquitylation during the early phase of the disease pathology .

What applications are Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibodies suitable for?

Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibodies are specifically designed to detect the acetylation of lysine 29 in ubiquitin proteins encoded by UBA52, RPS27A, UBB, and UBC genes. Based on the available data, these antibodies are validated for the following applications:

• Enzyme-Linked Immunosorbent Assay (ELISA): The antibody has been validated for ELISA with a recommended dilution of 1:20000 .

• Western Blot (WB): These antibodies can detect the acetylated forms of the target proteins in Western blot applications with recommended dilutions ranging from 1:500 to 1:2000 .

While not explicitly stated for the K29 antibody, related UBA52 antibodies have also been used in immunohistochemistry (IHC) and immunofluorescence (IF) applications . The optimal dilutions for specific applications should be determined by the end user through appropriate optimization experiments.

It's important to note that these antibodies are strictly for research use only (RUO) and must not be used in diagnostic or therapeutic applications .

What species reactivity is observed with Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibodies?

The Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibody shows cross-reactivity with multiple species, making it versatile for comparative studies across different model organisms. According to the available data, the antibody demonstrates reactivity with:

• Human samples

• Mouse samples

• Rat samples

Additional UBA52 antibodies (not specifically targeting the K29 acetylation site) have shown broader reactivity including:

• Human

• Rat

• Mouse

• Monkey

• Canine samples

How should Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibodies be stored and handled?

Proper storage and handling of antibodies are critical for maintaining their performance and extending their shelf life. For Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibodies, the following guidelines should be observed:

• Storage Buffer: These antibodies are typically supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide .

• Storage Temperature: For short-term use (one to two days), store at 2-8°C. For extended storage, keep at -20°C .

• Working Dilutions: Working dilution samples should be discarded if not used within 12 hours .

• Freeze-Thaw Cycles: Minimize repeated freeze-thaw cycles as they can lead to protein denaturation and loss of antibody activity. Aliquoting the antibody before freezing is recommended for antibodies that will be used multiple times.

• Safety Considerations: Note that the storage buffer contains sodium azide, which is toxic. Appropriate safety measures should be taken when handling the antibody.

Following these storage and handling guidelines will help ensure optimal antibody performance in experimental applications.

What is the significance of lysine 29 (K29) acetylation in UBA52/RPS27A/UBB/UBC proteins?

Lysine 29 (K29) acetylation represents a critical post-translational modification (PTM) in ubiquitin proteins that significantly alters their functional properties. This specific modification has been implicated in several key cellular processes:

• Regulation of Protein Degradation: K29 acetylation can interfere with ubiquitin chain formation at this site, potentially modulating protein degradation pathways. Since K29 is also a site for ubiquitination, acetylation at this position may serve as a regulatory mechanism to prevent ubiquitin chain extension .

• DNA Repair Mechanisms: Research indicates that K29 acetylation plays a role in DNA damage response pathways, potentially by regulating the stability or activity of repair proteins .

• Cell Cycle Progression: K29 acetylation has been linked to cell cycle control, possibly by influencing the degradation timing of cell cycle regulators .

The table below summarizes the post-translational modifications observed at K29 in UBA52:

The interplay between these different modifications (acetylation, sumoylation, and ubiquitination) at the same residue suggests a complex regulatory network that fine-tunes protein function based on cellular context . Understanding K29 acetylation is particularly important in neurodegenerative disease research, where abnormal post-translational modifications of ubiquitin can contribute to protein aggregation and pathology .

How can researchers validate the specificity of Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibodies?

Validating antibody specificity is critical for ensuring reliable experimental results. For Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibodies, researchers should implement the following validation strategies:

• Peptide Competition Assay: Pre-incubate the antibody with the synthetic acetylated peptide used as the immunogen (derived from the human Ub around the acetylation site of K29). A significant reduction in signal should be observed if the antibody is specific .

• K29 Mutant Analysis: Compare antibody reactivity between wild-type samples and those expressing K29R or K29A mutants of the target proteins. These mutations prevent acetylation at position 29, so specific antibodies should show reduced or no signal with the mutants.

• Deacetylase Treatment: Treat samples with histone deacetylases (HDACs) or sirtuin deacetylases prior to analysis. A decrease in signal after deacetylase treatment indicates acetylation-specific recognition.

• Specificity for Acetylation vs. Other PTMs: Since K29 can also be ubiquitinated or sumoylated, confirm that the antibody doesn't cross-react with these modifications by comparing signals from samples with different PTMs .

• Mass Spectrometry Correlation: Correlate antibody-based detection with mass spectrometry identification of acetylated K29 in the same samples.

• Western Blot Analysis: When performing western blots, include both positive controls (samples known to contain acetylated K29) and negative controls (samples where K29 acetylation is absent or removed) .

Implementation of multiple validation approaches provides stronger evidence for antibody specificity and increases confidence in experimental results.

What experimental considerations are important when investigating UBA52 cleavage and its role in ubiquitination?

Investigating UBA52 cleavage and its subsequent role in ubiquitination requires careful experimental design and consideration of several key factors:

• Detection of Cleavage Products: UBA52 is cleaved into ubiquitin and ribosomal protein L40 (RPL40). Use appropriate antibodies to detect both cleaved products. Anti-UBA52 antibodies can detect RPL40 and endogenous RPL40, while specific anti-ubiquitin antibodies can detect the released ubiquitin .

• Cleavage-Resistant Mutants: Employ cleavage-resistant UBA52 mutants as controls. For example, mutations in the terminal region of ubiquitin (G75/76A) can generate cleavage-resistant UBA52 that shows decreased high-molecular weight smear compared to wild-type UBA52 .

• Visualization Strategies: Consider using tagged constructs such as FLAG-UBA52-GFP to monitor cleavage and subsequent ubiquitination. This approach allows for tracking both the cleaved products and the ubiquitination process .

• Proteasome Inhibitors: Use proteasome inhibitors (e.g., MG132) to prevent degradation of ubiquitinated proteins, which can enhance detection of ubiquitination events mediated by UBA52-derived ubiquitin.

• Deubiquitinating Enzyme (DUB) Inhibitors: Consider using DUB inhibitors to prevent removal of ubiquitin chains, which can also enhance detection of ubiquitination.

• Time-Course Experiments: Implement time-course experiments to track the kinetics of UBA52 cleavage and subsequent ubiquitination events.

• Thioflavin-S Assay: This technique can be valuable for assessing protein fibril formation in relation to UBA52 function, particularly in neurodegenerative disease models .

A systematic investigation incorporating these considerations can provide valuable insights into the role of UBA52 in ubiquitination processes and its implications in various cellular contexts, particularly in pathological conditions like Parkinson's disease .

How does the acetylation of UBA52/RPS27A/UBB/UBC at K29 impact neurodegenerative disease mechanisms?

The acetylation of ubiquitin-coding genes at lysine 29 has significant implications for neurodegenerative disease pathophysiology, particularly in the context of Parkinson's disease (PD) and related disorders:

• Protein Aggregation Modulation: Acetylation at K29 may influence the formation and clearance of protein aggregates, which are hallmarks of neurodegenerative diseases. In Parkinson's disease, UBA52 has been specifically implicated in the early phase of disease pathology through its role in the ubiquitin-proteasome system (UPS) .

• HSP90 Ubiquitylation: UBA52 plays a crucial role in HSP90 ubiquitylation during the early phase of Parkinson's disease. HSP90 (Heat Shock Protein 90) is a molecular chaperone involved in protein folding and stabilization. Altered acetylation at K29 may affect UBA52's ability to participate in this ubiquitylation process, potentially impacting protein homeostasis in neurons .

• Interference with Ubiquitin Chain Formation: K29 is a site for ubiquitin chain formation, and acetylation at this position could interfere with K29-linked ubiquitin chains. These chains have been implicated in protein degradation pathways relevant to neurodegenerative diseases .

• α-Synuclein Pathology: Research using α-synuclein-PFFs treated cells and rotenone-induced sporadic models of PD suggests interactions between UBA52 and α-synuclein pathology. Alterations in UBA52 acetylation may affect these interactions and subsequent disease progression .

• Therapeutic Implications: Understanding the role of K29 acetylation provides potential therapeutic targets. Modulating this acetylation could potentially influence disease progression by restoring normal protein degradation pathways and reducing pathological protein aggregation.

When investigating these mechanisms, researchers should consider employing multiple experimental approaches, including the use of Thioflavin-S assays to assess protein fibril formation, confocal microscopy to visualize localization/co-localization of α-synuclein and UBA52, and both in vitro and in vivo models of neurodegenerative diseases .

What technical challenges might researchers encounter when using Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibodies, and how can these be addressed?

Researchers working with Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibodies may encounter several technical challenges that can impact experimental outcomes. Here are key challenges and strategies to address them:

• Cross-Reactivity with Other Acetylated Lysines:

  • Challenge: The antibody may recognize acetylated lysines at other positions or in other proteins.

  • Solution: Validate specificity using peptide competition assays with acetylated peptides corresponding to K29 and other lysines. Include appropriate controls such as K29R mutants in experimental designs.

• Low Abundance of K29 Acetylation:

  • Challenge: K29 acetylation may occur at low levels in physiological conditions, making detection difficult.

  • Solution: Enrich acetylated proteins using immunoprecipitation prior to detection. Consider using histone deacetylase inhibitors (HDACi) to increase acetylation levels for initial validation experiments.

• Interference from Other Post-Translational Modifications:

  • Challenge: K29 can also be ubiquitinated or sumoylated, potentially interfering with antibody recognition .

  • Solution: Use mass spectrometry to confirm the presence and nature of modifications at K29. Compare results from samples with different PTM profiles.

• Sample Preparation Effects on Epitope Accessibility:

  • Challenge: Fixation methods for immunohistochemistry or sample preparation for Western blot may affect epitope recognition.

  • Solution: Optimize fixation protocols and test multiple sample preparation methods. For Western blots, try both reducing and non-reducing conditions.

• Antibody Dilution Optimization:

  • Challenge: Recommended dilutions (1:500-1:2000 for WB; 1:20000 for ELISA) may not be optimal for all experimental conditions.

  • Solution: Perform titration experiments to determine optimal antibody concentrations for specific applications and sample types.

• Distinguishing Between UBA52, RPS27A, UBB, and UBC:

  • Challenge: The antibody recognizes acetylated K29 in all four ubiquitin-coding genes, making it difficult to determine which specific protein is detected.

  • Solution: Combine the acetylation-specific antibody with antibodies specific to each protein. Alternatively, use genetic approaches (knockdown/knockout) to eliminate specific ubiquitin-coding genes.

• Temporal Dynamics of Acetylation:

  • Challenge: K29 acetylation may be transient or change with cellular conditions.

  • Solution: Perform time-course experiments and examine acetylation under various cellular stresses or treatments relevant to the research question.

Addressing these challenges through careful experimental design and validation will enhance the reliability and interpretability of research results when using these antibodies.

What emerging research areas could benefit from studying UBA52/RPS27A/UBB/UBC K29 acetylation?

The study of K29 acetylation in ubiquitin-coding genes opens numerous avenues for cutting-edge research across multiple disciplines:

• Neurodegenerative Disease Mechanisms: Further investigation into the role of UBA52 in Parkinson's disease and other neurodegenerative disorders could reveal novel pathogenic mechanisms and therapeutic targets. The involvement of UBA52 in HSP90 ubiquitylation suggests its importance in protein quality control systems relevant to neurodegeneration .

• Cancer Biology: Given the critical role of ubiquitination in regulating cell cycle progression and DNA repair, investigating K29 acetylation could provide insights into cancer development and progression. Dysregulation of protein acetylation has been linked to various cancers.

• Proteostasis and Aging: The ubiquitin-proteasome system is crucial for maintaining protein homeostasis, which declines with age. Understanding K29 acetylation's impact on UPS function could illuminate mechanisms of cellular aging and age-related diseases.

• Drug Development: Targeting the enzymes responsible for K29 acetylation or deacetylation could lead to novel therapeutic approaches for diseases characterized by protein aggregation or aberrant protein degradation.

• Systems Biology: Integrating data on K29 acetylation with other post-translational modifications at this site (ubiquitination, sumoylation) could help develop comprehensive models of cellular signaling networks.

• Structural Biology: Investigating how K29 acetylation affects ubiquitin structure and its interactions with ubiquitin-binding domains could provide fundamental insights into ubiquitin biology.

• Immunology: Given ubiquitin's role in immune signaling, exploring K29 acetylation could reveal novel regulatory mechanisms in immune responses.

Researchers entering these fields should consider employing multidisciplinary approaches, combining biochemical techniques with advanced imaging, proteomics, and in vivo models to fully elucidate the biological significance of K29 acetylation in different contexts.

What methodological advancements could improve the study of acetylation in ubiquitin-coding genes?

Advancing the study of acetylation in ubiquitin-coding genes requires innovative methodological approaches that address current technical limitations:

• Site-Specific Acetyllysine Antibodies: Development of highly specific antibodies that can distinguish between acetylation at different lysine residues (K6, K11, K27, K29, K33, K48, K63) in ubiquitin would enable more precise analysis of acetylation patterns .

• Proximity Ligation Assays (PLA): Adaptation of PLA technology for detecting acetylated ubiquitin in situ would allow visualization of acetylation events in their native cellular context with high sensitivity.

• Genetic Code Expansion: Incorporating acetyllysine directly during protein synthesis using genetic code expansion techniques would enable the production of homogeneously acetylated ubiquitin for structural and functional studies.

• Mass Spectrometry Innovations: Development of enhanced mass spectrometry methods with improved sensitivity for detecting low-abundance acetylation events and distinguishing between closely related ubiquitin proteins.

• CRISPR-Based Acetylation Reporters: Creating genomically integrated reporters that respond to specific acetylation events could enable real-time monitoring of ubiquitin acetylation in living cells.

• Optogenetic Control of Acetylation: Engineering light-controlled acetyltransferases or deacetylases to manipulate acetylation levels at specific times and in specific cellular compartments.

• Single-Molecule Techniques: Application of single-molecule imaging or force spectroscopy to study how acetylation affects individual ubiquitin molecules and their interactions with binding partners.

• Computational Modeling: Development of advanced algorithms to predict the functional consequences of acetylation and its interplay with other post-translational modifications.

• Organ-on-a-Chip and 3D Culture Systems: Implementation of more physiologically relevant experimental systems to study acetylation in tissue-specific contexts, particularly for neurodegenerative disease research .